<DOC>
	<DOCNO>NCT01133483</DOCNO>
	<brief_summary>The purpose study 1 . Compare evaluate single dose , crossover , bioequivalence study Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets Allegra-D 24 hr tablet . 2 . Monitor adverse event ensure safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets Dr.Reddy 's Under Fed Conditions</brief_title>
	<detailed_description>An open label , balance , randomize , two-treatment , two-period , two-sequence , single dose , crossover bioequivalence study Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets Dr. Reddy 's Allegra-D 24 hour ER Tablets Aventis Pharmaceuticals Inc. , USA healthy , adult , human subject feed condition .</detailed_description>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Human subject age 18 45 year ( include ) Subjects'weight within normal range accord normal value Body Mass Index ( 18.5 24.9kgm2 ) minimum 50 kg weight . Subjects normal health determine personal medical history clinical examination laboratory examination within clinically acceptable normal range . Subjects normal 12lead electrocardiogram ( ECG ) . Subjects normal chest XRay ( P/A view ) . Have negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . Have negative alcohol breath test . Subjects willing adhere protocol requirement provide write informed consent . Subjects exclude study , meet follow criterion : Hypersensitivity Fexofenadine Hydrochloride Pseudoephedrine Hydrochloride relate drug . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . History presence significant alcoholism drug abuse past one year . History presence significant smoking ( 10 cigarette beedi's/day ) . History presence significant asthma , urticaria allergic reaction . History presence significant gastric and/or duodenal ulceration . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumour . History presence cancer . Difficulty donate blood . Difficulty swallow solid like tablet capsule . Systolic blood pressure le 100 mm Hg 140 mm Hg . Diastolic blood pressure less SO mm Hg 90 mm Hg . Pulse rate less 50/minute 100/minute . Oral temperature le 95°F 98.5°F . Respiratory rate le 12/minute 20/minute SUbjects use prescription medication , within 14 day period 01 dose OTC medication within 14 day period 01 dosing . Major illness 3 month screen . Participation drug research study within past 3 month . Donation blood past 3 month screen . Subjects consume xanthinecontaining product ( include caffeine , theobromines , etc . ) within 48 hour prior period 01 dosing . Subjects consume food beverage contain grapefruit pomelo within 14 day prior period 01 dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride</keyword>
</DOC>